naphazoline has been researched along with Lung Diseases, Interstitial in 1 studies
Naphazoline: An adrenergic vasoconstrictor agent used as a decongestant.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carbone, RG | 1 |
| Monselise, A | 1 |
| Puppo, F | 1 |
1 other study available for naphazoline and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease: Is All Clear?
Topics: Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; | 2023 |